Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

BACKGROUND: A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with a significant improvement in progression-free surviva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Olson, Robert, Mathews, Lindsay, Liu, Mitchell, Schellenberg, Devin, Mou, Benjamin, Berrang, Tanya, Harrow, Stephen, Correa, Rohann J. M., Bhat, Vasudeva, Pai, Howard, Mohamed, Islam, Miller, Stacy, Schneiders, Famke, Laba, Joanna, Wilke, Derek, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Gaede, Stewart, Warner, Andrew, de Gruijl, Tanja D., Allan, Alison, Palma, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201684/
https://ncbi.nlm.nih.gov/pubmed/32370765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06876-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados